Ardelyx
Ardelyx
Explore linked clinical trials.4 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Assessing Tenapanor as a Treatment of CF-related Constipation. | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Infant, Newborn, Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, Digestive, constipation disorder, cystic fibrosis, hereditary disease, lung disorder, pancreas disorder, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-08-21 | NCT06810167 | |
| A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults | Chronic Idiopathic Constipation (CIC) | Recruiting | Phase 3 | 2026-06-04 | NCT07382167 | |
| Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C | Irritable Bowel Syndrome With Constipation (IBS-C) | Enrolling by invitation | Phase 3 | 2026-06-04 | NCT05905926 | |
| Tenapanor in Synucleinopathy-Related Constipation | Nutritional and Metabolic Diseases, Parkinson disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, Digestive, basal ganglia disorder, brain disorder, central nervous system disorder, constipation disorder, metabolic disease, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, proteostasis deficiencies, synucleinopathy | Recruiting | Phase 2 | 2025-02-10 | NCT06460038 |